[Form 3] Sol-Gel Technologies Ltd. Initial Statement of Beneficial Ownership

Sol-Gel Technologies Ltd. Chairman and CEO Moshe Arkin filed an initial ownership report showing his stake in the company.

Rhea-AI Filing Summary

Sol-Gel Technologies Ltd. Chairman and CEO Moshe Arkin filed an initial ownership report showing his stake in the company. He reports indirect ownership of warrants giving the right to buy 200,000 ordinary shares at an exercise price of $58.50 per share, expiring on January 27, 2028, through M. Arkin Dermatology Ltd. He also reports 143,257 ordinary shares held directly and 1,606,856 ordinary shares held indirectly through M. Arkin Dermatology Ltd. A footnote states he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Arkin Moshe

Role Chairman of Board and CEO

Type	Security	Shares	Price	Value
holding	Warrants (right to buy)	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrants (right to buy) — 200,000 contracts (Indirect, By M. Arkin Dermatology Ltd.); Ordinary Shares — 143,257 shares (Direct); Ordinary Shares — 1,606,856 shares (Indirect, By M. Arkin Dermatology Ltd.)

Footnotes (2)

1. F1. Ordinary shares, NIS 1.00 par value per share.
2. F2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 12:12 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Arkin Moshe

(Last) (First) (Middle)

C/O SOL-GEL TECHNOLOGIES LTD.

7 GOLDA MEIR STREET

(Street)

NESS ZIONA 7403650

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sol-Gel Technologies Ltd. [ SLGL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman of Board and CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	143,257	D
Ordinary Shares(1)	1,606,856(2)	I	By M. Arkin Dermatology Ltd.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (right to buy)	01/07/2023	01/27/2028	Ordinary Shares(1)	200,000(2)	$58.5	I	By M. Arkin Dermatology Ltd.

Explanation of Responses:

1. Ordinary shares, NIS 1.00 par value per share.

2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit 24 - Power of Attorney

	/s/Eyal Ben-Or, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)